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patients (22% of those treated with one-daily dosing). Those
subjects showed lower values in several dimensions of the quality
of life. This is a new way to estimate the GPAO and HTO preva-
lence. This allowed to give a useful approximation to profes-
sionals involved in ocular diseases medical, economical and
societal management. CONCLUSION: On the basis of this ﬁrst
nationwide study, it can be estimated that the prevalence of 
subjects treated with IOP-lowering topical medications is about
1.2 million in France. Number of daily doses appear to inﬂuence
compliance.
EYE—Cost Studies
PEY3
THE ECONOMIC IMPACT OF BLUE-LIGHT FILTERING
INTRAOCULAR LENSES ON AGE-RELATED MACULAR
DEGENERATION ASSOCIATED WITH CATARACT SURGERY
Reddy P1, Gao X2, Barnes R3, Fairchild C3, Boci K2,Waycaster C3,
Pashos CL1
1Abt Associates Inc, Lexington, MA, USA, 2Abt Associates Inc,
Bethesda, MD, USA, 3Alcon Laboratories Inc, Fort Worth,TX, USA
OBJECTIVES: Epidemiological data support an association
between age-related macular degeneration (AMD) and cataract
surgery that may be attributed to post-operative blue light expo-
sure. By limiting the retina’s blue light exposure, new blue-light
ﬁltering intraocular lenses (BLF IOLs) have the potential to
reduce the development of AMD following cataract surgery. In
the current economic healthcare environment, there is increased
interest in the cost-effectiveness of new medical technologies.
The objective of this analysis was to evaluate the cost-effective-
ness of a BLF IOL versus a non-BLF IOL in cataract surgery.
METHODS: An economic model was developed to emulate
three age-speciﬁc cohorts and to assess the clinical and economic
outcomes over 5 years. Data from the published literature was
supplemented with clinical expert opinion. Key clinical inputs
were the risk of AMD after cataract surgery and the effective-
ness of the BLF IOL in reducing the risk of AMD. Direct medical
costs including the cost of the IOL, monitoring, and AMD pro-
phylaxis and treatment were incorporated into the model. All
costs were standardized to 2004 US dollars. Age-stratiﬁed base-
case and sensitivity analyses were conducted. RESULTS: In the
BLF IOL group, the 5-year age-stratiﬁed incidence of AMD
ranged from 0.58 to 9.23 per 100 eyes, compared with 1.69 to
24.55 per 100 eyes in the non-BLF IOL group. The incremental
cost of the BLF was offset by reduced costs associated with
averted AMD treatment. Estimated savings with BLF IOLs per
100 eyes were $4275, $29,997, and $111,734 in the 55 to 64
year-old, 65 to 74 year-old, and ≥75-year-old cohorts, respec-
tively; these ﬁndings remained robust across the sensitivity analy-
ses. CONCLUSION: This study suggests that the economic
beneﬁts of implanting BLF IOLs during cataract surgery are
observed in all patients although cost savings are greatest in
patients ≥75 years.
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OBJECTIVE: Exudative age-related macular degeneration
(AMD) is the most common cause of blindness among older
Americans in the United States. No substantive information on
costs for exudative AMD was found in the literature. This study
estimates incremental costs for the disease. METHODS: Seven
years (1994–2000) of 5% sample of Medicare medical claims
data from the Standard Analytical File (SAF) was used. We fol-
lowed AMD and control patients with an index date starting in
1996 for two years. Incremental cost was deﬁned as the excess
cost for exudative AMD cohort over that of an age-gender-
matched non-exudative-AMD group based on Medicare reim-
bursed expenditures. We also estimated the 10-year projected
cost using Medical Price Index. Cost from AMD related comor-
bid conditions, such as depression which could worsen as the
result of the progression in exudative AMD, were evaluated indi-
vidually. RESULTS: A total of 3059 wet AMD patients were
identiﬁed and a cohort of non-wet-AMD with same size was also
created. Two years’ incremental medical cost for wet AMD
patients compared to the controlled cohort is $2689, including
$485 (18%) for inpatient hospital, $1132 (42%) for outpatient
hospital, and $1034 (38%) for ofﬁce visits. The 10-year pro-
jected cost was $16,148, including $6795 for outpatient hospi-
tal and $6207 for ofﬁce visit. Incremental cost of depression
almost doubled 1 year after the diagnosis of wet AMD, increas-
ing from $64/year to $118/year. CONCLUSION: Excess cost for
wet AMD after initial diagnosis was substantial. This research
does not incorporate Medicaid covered expenses and out of
pocket costs. With the aging population and people living longer,
the economic burden of this disease will increase. This informa-
tion may help researchers and policy makers in assessing beneﬁt
and increase use of approved AMD therapies, such as Macugen
(pegaptanib sodium) to help determine the clinical and economic
beneﬁts to patients and society.
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OBJECTIVES: ARMD is the leading cause of blindness for
people aged 60 and over in the US, resulting in signiﬁcant visual
ﬁeld losses, and consequent occurrences of serious vision-related
conditions and events, reductions in health-related quality of life,
and economic costs. The research objective was to assess the
incremental cost-utility of Visudyne®, relative to usual care of
ARMD. METHODS: A Markov cohort model was developed to
simulate progressive loss of visual acuity, treatment alternatives
and consequent clinical events and costs. Efﬁcacy of Visudyne®
was based on pooled results of three two-year randomized
placebo-controlled trials, and extrapolated to a horizon of 15
years. Treatment was assumed to be discontinued after two
years. Extrapolation of clinical trial results for both the treat-
ment and usual care arms of the model were based on the usual
care outcomes. Patients were grouped based on lesion type and
size. Relative risks and costs of serious clinical events (e.g., hip
fractures, nursing home placement), and utilities associated with
levels of visual acuity were derived from the literature. Incre-
mental cost-effectiveness ratios (ICERs) were expressed as 2004
US dollars per quality-adjusted life year ($/QALY). One-way sen-
sitivity analyses were performed with respect to efﬁcacy, the pro-
portion of patients receiving treatment for the better-seeing eye,
and other clinical, utility, and cost parameters. RESULTS: The
ICER of Visudyne® was $35,200/QALY, and was most sensitive
to the proportion of patients whose treatment was in the better-
seeing eye, the source for utilities, and the distribution of patients
